The company recognized grant revenue of $1.1M for the three months ended December 31, 2025 as compared to $1.2M in the comparable period in 2024, which represents MTEC’s share of the costs incurred for the company’s AP-SA02 program for the treatment of Staphylococcus aureus bacteremia.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARMP:
- Armata Highlights AP-SA02 Progress Amid Earnings Release Delay
- Armata Pharmaceuticals delays announcement of Q4, FY25 results
- ARMP Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Armata price target raised to $15 from $9 at H.C. Wainwright
- Armata Gains QIDP Status for AP-SA02 Bacteremia Therapy